The Senate invoked cloture Wednesday afternoon with a vote of 53–47, a party-line split. In response, Democrats decided not ...

While Pelosi has yet to publicly announce her 2026 candidacy, she has filed the requisite paperwork to run. And even with the ...

One of Robert F. Kennedy Jr.’s most devoted cheerleaders, Dr. Patrick Soon-Shiong, the billionaire owner of the Los Angeles ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

Energy equipment manufacturer GE Vernova saw its share prices grow by 8.42 percent on Thursday to close at $382.94 apiece as ...

We recently compiled a list of the 12 Stocks That Will Double in 2025. In this article, we are going to take a look at where ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

In this article, we will take a look at the 12 stocks that will double in 2025.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

ImmunityBio shares were up 14% to $3.52 after the company entered into a collaboration and supply agreement with BeiGene. The two companies will conduct a confirmatory randomized Phase 3 clinical ...